Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

Background: Tumour necrosis factor α (TNFα) is a major therapeutic target in a range of chronic inflammatory disorders characterised by a Th1 type immune response in which TNFα is generated in excess. By contrast, asthma is regarded as a Th2 type disorder, especially when associated with atopy. However, as asthma becomes more severe and chronic, it adopts additional characteristics including corticosteroid refractoriness and involvement of neutrophils suggestive of an altered inflammatory profile towards a Th1 type response, incriminating cytokines such as TNFα.

Methods: TNFα levels in bronchoalveolar lavage (BAL) fluid of 26 healthy controls, 42 subjects with mild asthma and 20 with severe asthma were measured by immunoassay, and TNFα gene expression was determined in endobronchial biopsy specimens from 14 patients with mild asthma and 14 with severe asthma. The cellular localisation of TNFα was assessed by immunohistochemistry. An open label uncontrolled clinical study was then undertaken in 17 subjects with severe asthma to evaluate the effect of 12 weeks of treatment with the soluble TNFα receptor-IgG1Fc fusion protein, etanercept.

Results: TNFα levels in BAL fluid, TNFα gene expression and TNFα immunoreactive cells were increased in subjects with severe corticosteroid dependent asthma. Etanercept treatment was associated with improvement in asthma symptoms, lung function, and bronchial hyperresponsiveness.

Conclusions: These findings may be of clinical significance in identifying TNFα as a new therapeutic target in subjects with severe asthma. The effects of anti-TNF treatment now require confirmation in placebo controlled studies.

Asthma is a disorder of the conducting airways characterised by Th2 mediated inflammation, with recruitment of a range of inflammatory cells and enhanced mediator release. In mild disease the inflammatory response, attendant bronchial hyperresponsiveness (BHR), and variable airflow obstruction are highly responsive to inhaled corticosteroids, positioning these drugs as first line controller therapy for this disease. However, in persistent and severe asthma, inhaled corticosteroids are only partially effective, and patients often require intermittent or continuous oral corticosteroids. This severe end of the disease spectrum, which exhibits an altered inflammatory cell profile involving neutrophils and accounts for approximately 10% of the asthmatic population, represents an important unmet clinical need as it is these patients who have the highest morbidity and mortality.

Tumour necrosis factor α (TNFα) is a major therapeutic target in a range of chronic inflammatory disorders involving neutrophils. These include rheumatoid arthritis, juvenile arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, glomerulonephritis, sarcoidosis and Behcet’s disease, all of which are characterised by a Th1 type immune response associated with excess generation of TNFα. Although asthma is considered an eosinophilic disorder involving Th2 cytokines, there has been some interest in the TNF family of cytokines, especially TNFα. In murine models of asthma, a deficiency in TNFα receptors, chronic treatment with a TNFα antibody, or induction of a TNFα autoantibody results in marked attenuation of antigen induced airway inflammation. Genetic association studies have also shown a strong association between TNFα gene polymorphism and BHR and asthma, and inhalation of TNFα in both rodents and normal or asthmatic humans leads to the development of BHR accompanied by airway neutrophilia. Many different cell types produce TNFα, but those especially relevant to asthma include T lymphocytes, monocytes/macrophages, mast cells, eosinophils and epithelial cells. Importantly, TNFα promotes recruitment of neutrophils, as well as eosinophils, into the airways through functional effects on the endothelium and by direct and indirect chemotactic effects. Recognising the unmet need in severe persistent asthma, we investigated the potential of TNFα as a therapeutic target in this disease.

METHODS
The studies were approved by the Southampton and West Hampshire local research ethics committees and volunteers gave their written informed consent.

Clinical assessment and subject classification
Healthy non-asthmatic subjects and mild asthmatic subjects were recruited from a research database of volunteers, and subjects with severe asthma were identified from outpatient clinics. Detailed clinical history and physical examination were performed on all subjects. Spirometric tests and assessment of asthma severity were in accordance with the BTS/SGIN guidelines. All subjects were tested for atopy by skin prick testing and were free from respiratory tract
infections for a minimum of 4 weeks before inclusion in the study. The characteristics of the groups of subjects enrolled into the various arms of the study are summarised in Table 1.

**Fibreoptic bronchoscopy**

Subjects underwent fibreoptic bronchoscopy under local anaesthesia as previously described using an Olympus BFIT20 bronchoscope (Olympus, Tokyo, Japan). Bronchoalveolar lavage (BAL) fluid was obtained by wedging the bronchoscope into a segmental bronchus and introducing six 20 ml aliquots of 0.9% saline, pre-warmed to 37°C. Gentle suction was used to collect the fluid into a 100 ml plastic trap. The lavage fluid was centrifuged at 400 g for 10 minutes at 4°C and the supernatant aliquoted and stored at 80°C. The number of TNFα positive cells was determined by counting the total number of TNFα immunoreactive cells within the biopsy section, excluding areas of muscle, large blood vessels, glands, damaged tissue and artefact. Counts were made in two separate tissue sections cut at least 10 µm apart, and the mean number of cells calculated. Only cells with an identifiable nucleus were counted. The area of the final volume of 12.5 mm².

**TNFα mRNA expression**

For analysis of TNFα gene expression, total RNA was extracted from individual biopsy specimens. One microgram of total RNA was reverse transcribed using the reverse transcription (RT) System (Promega, Southampton, UK) according to the manufacturer’s instructions. TNFα primer (Qiagen) and probe (Eurogentec, Seraing, Belgium) sequences labelled with a 5’-reporter dye FAM (6-carboxyfluorescin) and a 3’-Eclipse DARK quencher™ were: forward primer 5’-GGTGAGGCTCTGGAAGGCTGAG-3’; reverse primer 5’-GGTGGAGGCTCTGGAAGGCTGAG-3’; and probe FAM-5’-AACAACCTCTCAGAGCCATACACAGTACAGA-3’-Eclipse. Random hexamers were used to reverse transcribe total RNA as 18S ribosomal RNA (18S rRNA) was the endogenous control. For each duplicate sample the PCR reaction contained 25 ng of total RNA was reverse transcribed using the reverse transcription (RT) System (Promega, Southampton, UK) according to the manufacturer’s instructions. TNFα primer (Qiagen) and probe (Eurogentec, Seraing, Belgium) sequences labelled with a 5’-reporter dye FAM (6-carboxyfluorescin) and a 3’-Eclipse DARK quencher™ were: forward primer 5’-GGTGAGGCTCTGGAAGGCTGAG-3’; reverse primer 5’-GGTGGAGGCTCTGGAAGGCTGAG-3’; and probe FAM-5’-AACAACCTCTCAGAGCCATACACAGTACAGA-3’-Eclipse. Random hexamers were used to reverse transcribe total RNA as 18S ribosomal RNA (18S rRNA) was the endogenous control. For each duplicate sample the PCR reaction contained 25 ng of cDNA template, 3.2 pM fluorogenic probe, 15 pM forward and reverse primers, and 7.5 µl qPCR mix (Eurogentec) in a final volume of 12.5 µl. Separate normalising controls were run which contained 1 µl of 18S rRNA and probe mixes (Eurogentec). RT negative samples were used to indicate that

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Subject details presented for the whole study group and for each separate study group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TNFα study and patient groups</strong></td>
<td><strong>Sex (M/F)</strong></td>
</tr>
<tr>
<td>All subjects</td>
<td></td>
</tr>
<tr>
<td>Healthy controls</td>
<td>26</td>
</tr>
<tr>
<td>Mild asthma</td>
<td>67</td>
</tr>
<tr>
<td>Severe asthma</td>
<td>51</td>
</tr>
<tr>
<td><strong>Lavage studies</strong></td>
<td></td>
</tr>
<tr>
<td><em>Comparator study</em></td>
<td></td>
</tr>
<tr>
<td>Healthy controls</td>
<td>26</td>
</tr>
<tr>
<td>Mild asthma</td>
<td>42</td>
</tr>
<tr>
<td>Severe asthma</td>
<td>20</td>
</tr>
<tr>
<td><strong>Biopsy studies</strong></td>
<td></td>
</tr>
<tr>
<td>Gene expression</td>
<td></td>
</tr>
<tr>
<td>Mild asthma</td>
<td>14</td>
</tr>
<tr>
<td>Severe asthma</td>
<td>14</td>
</tr>
<tr>
<td>Immunohistochemistry</td>
<td></td>
</tr>
<tr>
<td>Mild asthma</td>
<td>42</td>
</tr>
<tr>
<td>Severe asthma</td>
<td>14</td>
</tr>
<tr>
<td><strong>Etanercept study</strong></td>
<td></td>
</tr>
<tr>
<td>Severe asthma</td>
<td>17</td>
</tr>
</tbody>
</table>

Differences between the groups and the healthy control subjects with respect to FEV1% predicted are designated by *p*<0.01, **p*<0.001 and ***p*<0.0001, while differences for the same measure between the mild and severe asthmatic groups are indicated as †*p*<0.001 and ††*p*<0.0001.

The different subject groups were defined on the following basis:

(a) Healthy control subjects had no history or symptoms to suggest asthma, normal lung function and normal bronchial reactivity, as reflected by a PC20 methacholine of >16 mg/ml.

(b) Mild asthma was defined on the basis of a doctor diagnosis of asthma, current symptoms compatible with asthma, the need for the use of prn salbutamol for symptom relief but no other medication use for asthma.

(c) Severe asthma was defined on the basis of doctor diagnosis and treated asthma that remained symptomatic, despite treatment at stage 4/5 of the BTS/SIGN guidelines, together with historical data of airway reversibility and the need for oral steroid therapy, either as regular maintenance therapy or for the treatment of exacerbations. Thirty seven of the 51 severe asthmatics were on maintenance oral steroid therapy for their disease control in addition to high dose inhaled steroids, long acting β agonists, and additional treatment such as leukotriene receptor antagonists and theophyllines.

---

**Immunodetection of TNFα**

BAL fluid was concentrated 10–30 fold using Amicon Centriprep YM-3 centrifugal filter devices (Millipore, UK Ltd, Watford, UK) before measurement of TNFα by ELISA (R&D Systems, Abingdon, Bucks, UK). The assay had a lower limit of detection of 60 fg/ml and a coefficient of variation of repeated measures of 3.4%. Data are corrected for concentration and thus represent uncentrurated BAL fluid values.

Immunohistochemical staining for TNFα was conducted as previously described using a murine monoclonal antibody against human TNFα (1:500, R & D Systems). The specificity of the antibody was confirmed by omitting the primary antibody and replacing it with an isotype matched antibody. The number of TNFα positive cells was determined by counting the total number of TNFα immunoreactive cells within the biopsy section, excluding areas of muscle, large blood vessels, glands, damaged tissue and artefact. Counts were made in two separate tissue sections cut at least 10 µm apart, and the mean number of cells calculated. Only cells with an identifiable nucleus were counted. The area of the individual biopsy samples was measured using image analysis (Colorvision 1.7.6, Improvision, Coventry, UK), excluding those areas not included in the counting, and the data corrected to counts per mm².
the signals obtained were RT dependent. The PCR protocol was as follows: 95°C, 10 minutes, followed by 40 cycles of denaturation 95°C, 15 seconds, and annealing/extension 60°C, 1 minute. Thermocycling and real time detection of PCR products were performed on an iCyclerIQ sequence detection system (Bio-Rad, Hercules, CA, USA) and, following completion of the PCR reaction, the thresholds for fluorescence emission baseline were set automatically at 10 times the background levels on the FAM layer. Expression levels were normalised to the 18S rRNA levels and then expressed relative to the lowest expression value found in mild asthma using the ΔΔCT method. Samples were measured in duplicate.

**Proof of principle clinical study evaluating the effect of etanercept in severe asthma**

Seventeen subjects (12 women) of median age 43 years (range 30–67) with a mean (SD) duration of asthma of 23.8 (11.7) years were enrolled into the trial. Their mean (SD) resting forced expiratory volume in 1 second (FEV1) was 68.3 (5.0)% predicted. These patients were similar to those studied in the bronchoalveolar lavage and biopsy studies, being at stage 5 of the BTS/SIGN asthma management guidelines, requiring treatment with high dose inhaled corticosteroids (equivalent to beclometasone 2500 μg/day) and oral prednisolone (mean dose 11.5 mg/day). In addition to long acting β2 agonists, theophylline and leukotriene modifying drugs, all the subjects required prn salbutamol on an as required basis, delivered either by metered dose inhaler or by nebuliser. Current smokers, subjects with a smoking history of more than 10 pack years, and those with other coexisting lung diseases, a history of tuberculosis, multiple sclerosis, lupus erythematosus, and other autoimmune diseases were excluded.

Each patient received subcutaneous etanercept (Enbrel, Wyeth Laboratories, Berkshire, UK) 25 mg twice weekly as add-on therapy for 12 weeks. The dose of medication and the duration of treatment were chosen from the initial trials of etanercept in rheumatoid arthritis. No change was made to their regular controller asthma medications during the 12 week treatment period and all reliever medications except bronchodilators were kept constant throughout the study.

The primary efficacy variable was improvement in asthma control and the secondary outcome measures were changes in airway hyperresponsiveness to inhaled methacholine and lung function. The manufacturer of etanercept had no involvement in the design of the study.

Subjective asthma control, as measured by the Juniper asthma control questionnaire, was recorded on entry and completion, together with morning and evening peak expiratory flow (PEF) using Wright mini peak flow meters (the best of three) recorded daily in diary cards. Adverse events during the study period and use of regular rescue medication were also recorded. The clinic lung function was measured in duplicate.

**RESULTS**

**TNFα levels in BAL fluid and mRNA**

As the airway lumen is an important site of neutrophil accumulation in severe asthma, we first sought evidence for abnormal levels of TNFα in BAL fluid from asthmatic subjects with varying degrees of disease severity (table 1) and non-asthmatic controls. The severe asthmatics had significantly higher concentrations of TNFα (median 160 fg/ml (range 100–6660)) in BAL fluid than either the healthy controls (117 fg/ml (64–301) p = 0.001) or those with mild asthma (111 fg/ml (37–322), p = 0.001); the difference between the latter two groups was not significantly different (fig 1A). Relative TNFα mRNA levels were also significantly higher in biopsy specimens from the severe asthmatic subjects (median 2617 (range 58–276 488)) compared with mild asthmatic subjects (84 (1–1282); p = 0.002, fig 1B).

**TNFα levels in bronchial biopsy specimens**

To further identify the cellular source of TNFα protein, tissue sections of bronchial biopsies were examined by immunohistochemistry. This showed that TNFα expression was localised predominantly to mast cells, with occasional other cell types also showing some positive immunostaining. There were significantly greater numbers of TNFα immunoreactive cells/mm² in biopsy specimens from subjects with severe asthma (median 5.6 (range 0–62)) than in those from subjects with mild asthma (median 2.5 (range 0–26); p < 0.03, fig 1C and D).

**Clinical study with etanercept**

Seventeen patients (table 1) with severe asthma who were symptomatic despite receiving maximum inhaled corticosteroids were recruited into the open label study and received etanercept as add-on therapy for 12 weeks. Two of the 17 subjects enrolled into the study failed to complete it, one because of a swelling in the neck that was subsequently identified as a lipoma and the second developed a skin rash with the first dose of etanercept and was not keen to continue in the trial despite the rash resolving spontaneously.
The adverse events during etanercept treatment were mild (table 2).

Of the 15 subjects who completed the study, 12 weeks of treatment with etanercept resulted in a marked and highly significant improvement in symptoms with the mean (range) asthma control questionnaire score falling from 26 (9–32) to 11 (4–27), \( p < 0.001 \) (fig 2A). This was accompanied by a significant increase in baseline FEV1, FVC, and morning and evening PEF (table 3), and all but one of the patients discontinued their use of nebulised \( \beta_2 \) agonist. Of particular significance was the effect of etanercept in reducing BHR, with the provocative concentration of methacholine producing a 20% decrease in FEV1 (PC20) increasing from a geometric mean of 0.21 (0.1–0.64) mg/ml to 1.28 (0.53–2.92) mg/ml (fig 2B), representing a change of 2.5 doubling dilutions (table 3). Eight weeks after stopping etanercept, symptom scores and lung function had returned to pretreatment values.

Despite the severity of their asthma, we were able to obtain paired sputum samples from 11 of the 15 subjects involved in the study. However, although reductions in eosinophil and neutrophil numbers were observed in eight of the 11 subjects, this failed to achieve statistical significance.

### Table 2 Adverse events during treatment with etanercept

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>No (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin rash</td>
<td>6 (35.3)</td>
</tr>
<tr>
<td>Respiratory tract infections</td>
<td>10 (58.8)</td>
</tr>
<tr>
<td>Asthma exacerbations</td>
<td>9 (52.9)</td>
</tr>
<tr>
<td>Injection site reactions</td>
<td>4 (23.5)</td>
</tr>
<tr>
<td>Oral thrush</td>
<td>2 (11.2)</td>
</tr>
<tr>
<td>Joint pains</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>Nose bleed</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>Positive antinuclear antibody</td>
<td>3 (17.6)</td>
</tr>
</tbody>
</table>
were determined using the Wilcoxon rank sum test. (panel A) or geometric mean (panel B), interquartile range and 5–95% panels; the box and whisker plots (right hand panel) show median with median (panel A) or geometric mean (panel B) indicated (left hand panels); the box and whisker plots (right hand panel) show median with median (panel A) or geometric mean (panel B) indicated (left hand panels).

weeks 1 and 12 as a measure of the effect of etanercept on bronchial asthma24 and in those ventilated because of acute severe disease is a feature of more persistent and corticosteroid refractory asthma rather than of asthma per se. This extends previous reports in which increased TNFα concentrations in mild asthmatics and healthy controls. This suggests that the increase in TNFα seen in subjects with severe disease is a feature of more persistent and corticosteroid refractory asthma rather than of asthma per se. This extends previous reports in which increased TNFα concentrations have been reported in BAL fluid in symptomatic asthmaαα and in those ventilated because of acute severe disease.α5 We also found greater numbers of TNFα immunoreactive positive cells and greater gene expression for TNFα in endobronchial biopsy specimens from subjects with severe asthma than from those with symptomatic non-steroid treated asthma. As we have previously reported in biopsies from mild asthma,α9 this TNFα was localised predominantly to mast cell granules. Our findings in severe asthma were evident despite treatment with high dose inhaled corticosteroids and, in the majority, with additional oral corticosteroid therapy. Thus, not only is TNFα overexpressed within the airways of patients with severe disease, but current optimal treatment does not resolve this.

The therapeutic options for patients with corticosteroid dependent asthma are limited. These patients represent a clinical burden accounting for approximately 30% of the healthcare costs of asthma through multiple hospital admissions for exacerbations and the side effects of long term corticosteroids.α In other disease areas the appreciation that anti-TNFα strategies are able to modify disease that persists despite corticosteroid therapy led us to consider the potential benefit of anti-TNFα intervention strategies in the severe asthmatic group. We opted to use etanercept, which binds specifically to both TNFα and TNFβ thereby preventing free cytokine binding to cell surface TNF receptors.αα This was a proof of concept study and, as such, was open labelled and uncontrolled.

Etanercept treatment was associated with improvement in asthma symptoms, lung function, and BHR. It is unlikely that such changes would have arisen by chance in view of the chronic and persistent nature of the disease in these patients. However, the study cannot be considered conclusive as it was an open labelled study. Despite maximum doses of inhaled and oral corticosteroids, regular treatment with etanercept produced remarkable improvements in both clinical and physiological measures of asthma. The most striking feature was the improvement in BHR. When measuring BHR in asthma using repeated methacholine challenge, it is accepted that the error in PC20 determination is within one doubling dilution. Following experimental allergen exposure or natural allergen exposure, changes of 1–2 doubling dilutions in PC20 are considered clinically significant.αα Thus, although we had no data on which to base a power calculation before starting the study, our findings of an improvement of 2.5 doubling dilutions in PC20 is well outside the natural variation and in addition to any beneficial effect that may have already been achieved using inhaled and oral corticosteroids. At the end of the study the beneficial effects of etanercept were maintained for 2–4 weeks after asthma symptoms gradually returned to the pretreatment state.

The most common adverse effects encountered with etanercept were injection site reactions. The respiratory tract infections experienced by the four subjects would not be unusual in such patients with severe disease. It is difficult to suggest a causal association between the respiratory tract infections and the study medication as this was an open labelled study. The infections were associated with worsening of asthma control which was managed by increasing the dose of rescue medications. However, none of the subjects needed an increase in either their oral or inhaled corticosteroids.

DISCUSSION

Although asthma is considered an eosinophilic disorder,α7 at the severe end of the disease spectrum there is an altered inflammatory cell profile involving neutrophils.αα Consistent with this predominance of neutrophils,α4 αα we have shown that patients with severe corticosteroid dependent asthma have higher concentrations of TNFα in recovered BAL fluid. In contrast, no difference was seen between BAL fluid TNFα concentrations in mild asthmatics and healthy controls. This suggests that the increase in TNFα seen in subjects with severe disease is a feature of more persistent and corticosteroid refractory asthma rather than of asthma per se. This extends previous reports in which increased TNFα concentrations have been reported in BAL fluid in symptomatic asthmaαα and in those ventilated because of acute severe disease.α5 We also found greater numbers of TNFα immunoreactive positive cells and greater gene expression for TNFα in endobronchial biopsy specimens from subjects with severe asthma than from those with symptomatic non-steroid

![Figure 2](A) Symptom scores before and after treatment in 15 corticosteroid dependent severe asthmatic subjects treated with etanercept 25 mg twice weekly for 12 weeks. (B) Concentration of methacholine required to reduce FEV1 by 20% of baseline (PC20) at weeks 1 and 12 as a measure of the effect of etanercept on bronchial reactivity. Data shown are paired data before and after treatment with median (panel A) or geometric mean (panel B) indicated (left hand panels); the box and whisker plots (right hand panel) show median (panel A) or geometric mean (panel B), interquartile range and 5–95% confidence intervals with outliers shown as dots. Statistical significances were determined using the Wilcoxon rank sum test.

Table 3  Changes in lung function before and after treatment with etanercept

<table>
<thead>
<tr>
<th></th>
<th>Before treatment</th>
<th>After treatment</th>
<th>Mean change from baseline</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1 (l)</td>
<td>1.91 (0.5)</td>
<td>2.16 (0.6)</td>
<td>0.24 (0.18)</td>
<td>0.01</td>
</tr>
<tr>
<td>FVC (l)</td>
<td>2.55 (0.2)</td>
<td>2.88 (0.2)</td>
<td>0.33 (0.29)</td>
<td>0.03</td>
</tr>
<tr>
<td>Morning PEF (predicted %)</td>
<td>54.8 (5.6)</td>
<td>61.0 (5.8)</td>
<td>5.75 (5.65)</td>
<td>0.023</td>
</tr>
<tr>
<td>Evening PEF (predicted %)</td>
<td>55.3 (5.1)</td>
<td>63.9 (5.1)</td>
<td>8.64 (5.23)</td>
<td>0.006</td>
</tr>
<tr>
<td>Methacholine PC20 (mg/ml)*</td>
<td>0.21 (0.1 to 0.64)</td>
<td>1.28 (0.53 to 2.92)</td>
<td>2.5 (1.75)†</td>
<td>0.033</td>
</tr>
</tbody>
</table>

All values are mean (SE) except *geometric mean (95% CI). †Change shown as doubling dilutions of methacholine.
Inflammation Research, Division of Infection, Inflammation and Repair, A Reynolds, P H Howarth, K S Babu, H S Arshad, L Lau, M Buckley, W McConnell, P Beckett, M Al Ali, S J Wilson, D E Davies, S T Holgate, Allergy and Inflammation Research, Division of Infection, Inflammation and Repair, School of Medicine, Southampton General Hospital, Southampton, UK

**ACKNOWLEDGEMENTS**

The authors thank Miss Lorraine Hewitt for providing nursing care in association with bronchoscopies and Dr Rob M Powell who provided probe and primer sequences for TNFα quantitative PCR.

**REFERENCES**


www.thoraxjnl.com
A serum marker for the activity of pulmonary fibrosis in patients with systemic sclerosis

Assessing the activity of pulmonary fibrosis in patients with systemic sclerosis requires both bronchoalveolar lavage and serial high resolution computed tomography. A blood test for the diagnosis and monitoring of pulmonary fibrosis would be simpler and less invasive. Serum levels of KL-6 and SP-D show some correlation with severity and activity of disease, but are not particularly reliable. The authors assessed the usefulness of measuring serum levels of pulmonary and activation regulated chemokine (PARC). PARC is expressed at high levels in bronchoalveolar lavage fluid in patients with systemic sclerosis who have pulmonary fibrosis. It may be a marker of immune mediated fibrotic lung disease.

Serum levels of PARC were measured in 123 patients with systemic sclerosis and compared with levels in healthy controls and in patients with systemic lupus erythematosus. PARC levels were significantly higher in the systemic sclerosis group. In a retrospective longitudinal study, serum levels of PARC, KL-6 and SP-D were measured in 21 patients during active and inactive phases of pulmonary fibrosis. Of the three blood tests, PARC levels were found to reflect disease activity most accurately.

This paper does not evaluate the sensitivity of the PARC test in making a diagnosis of pulmonary fibrosis. It does, however, indicate that PARC may be useful in monitoring disease activity in established disease. It should be noted that PARC is not specific for pulmonary fibrosis in systemic sclerosis. Further analysis with a larger number of subjects is indicated.

A H N Gerratt
SHO in Respiratory Medicine, Hillingdon Hospital, Uxbridge, UK; AnnaGerratt@doctors.org.uk
A serum marker for the activity of pulmonary fibrosis in patients with systemic sclerosis

A H N Gerratt

Thorax 2005 60: 1018
doi: 10.1136/thx.2005.la0181

Updated information and services can be found at:
http://thorax.bmj.com/content/60/12/1018

These include:

References
This article cites 1 articles, 0 of which you can access for free at:
http://thorax.bmj.com/content/60/12/1018#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/